NCT03648151

Brief Summary

Radiomics is an attractive field in objectively quantifying image features, and may overcome the subjectivity of visually interpreting computed tomography (CT), or positron emission tomography (PET). It is reported that the features related to treatment response, outcomes, tumor staging, tissue identification, and cancer genetics. Therefore, the investigators try to explore the key features for the outcome of lung cancer patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2010

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
8.6 years until next milestone

First Submitted

Initial submission to the registry

August 21, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 27, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

July 23, 2020

Status Verified

July 1, 2020

Enrollment Period

10 years

First QC Date

August 21, 2018

Last Update Submit

July 22, 2020

Conditions

Lung CancerImage, Body

Keywords

Radomic featurePETCT

Outcome Measures

Primary Outcomes (1)

  • Overall survival (OS) of lung cancer patients

    The time from the scan date to death for any reason

    The patients were followed to December 31, 2019

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

lung caner

You may qualify if:

  • Pathologically diagnosed as lung caner.
  • Accepted PET/CT scans at the hospitals either affiliated to Shanxi Medical University or Anhui Medical University
  • Both PET and CT serials can be obtained
  • Can be followed for treatment modalities (including chemotherapy regimens, radiotherapy dose, and et al), survival time and status, and other related information.

You may not qualify if:

  • Simultaneously suffering from the cancers from other tissues and organs
  • Have a history of diabetes, chronic heart diseases, or chronic renal failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China

Location

First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

Location

Related Publications (7)

  • Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012 Feb;67(2):157-64. doi: 10.1016/j.crad.2011.08.012. Epub 2011 Sep 23.

    PMID: 21943720BACKGROUND

  • Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P. Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. J Nucl Med. 2017 Feb;58(2):282-287. doi: 10.2967/jnumed.116.179648. Epub 2016 Sep 22.

    PMID: 27660141BACKGROUND

  • Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3;5:4006. doi: 10.1038/ncomms5006.

    PMID: 24892406BACKGROUND

  • Yip SS, Kim J, Coroller TP, Parmar C, Velazquez ER, Huynh E, Mak RH, Aerts HJ. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer. J Nucl Med. 2017 Apr;58(4):569-576. doi: 10.2967/jnumed.116.181826. Epub 2016 Sep 29.

    PMID: 27688480BACKGROUND

  • Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016 Jul 7;61(13):R150-66. doi: 10.1088/0031-9155/61/13/R150. Epub 2016 Jun 8.

    PMID: 27269645BACKGROUND

  • Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 2017 Mar 23;7(1):358. doi: 10.1038/s41598-017-00426-y.

    PMID: 28336974BACKGROUND

  • Hongwei S, Xinzhong H, Huiqin X, Shuqin X, Ruonan W, Li L, Jianzhong C, Sijin L. Standard deviation of CT radiomic features among malignancies in each individual: prognostic ability in lung cancer patients. J Cancer Res Clin Oncol. 2023 Aug;149(10):7165-7173. doi: 10.1007/s00432-023-04649-7. Epub 2023 Mar 8.

    PMID: 36884114DERIVED

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Li Sijin, MD

    First Affiliated Hospital of Shanxi Medical University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief physician

Study Record Dates

First Submitted

August 21, 2018

First Posted

August 27, 2018

Study Start

January 1, 2010

Primary Completion

December 31, 2019

Study Completion

December 31, 2019

Last Updated

July 23, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations

CN(2)